140 related articles for article (PubMed ID: 16133533)
1. Chloroacetaldehyde: mode of antitumor action of the ifosfamide metabolite.
Brüggemann SK; Radike K; Braasch K; Hinrichs J; Kisro J; Hagenah W; Peters SO; Wagner T
Cancer Chemother Pharmacol; 2006 Feb; 57(3):349-56. PubMed ID: 16133533
[TBL] [Abstract][Full Text] [Related]
2. Ifosfamide metabolite chloroacetaldehyde inhibits cell proliferation and glucose metabolism without decreasing cellular ATP content in human breast cancer cells MCF-7.
Knouzy B; Dubourg L; Baverel G; Michoudet C
J Appl Toxicol; 2010 Apr; 30(3):204-11. PubMed ID: 19774546
[TBL] [Abstract][Full Text] [Related]
3. Necrotic pathway in human osteosarcoma Saos-2 cell death induced by chloroacetaldehyde.
Takahashi K; Sakurai K; Takahashi K; Tanaka H; Fujimoto Y
Anticancer Drugs; 2007 Jun; 18(5):543-53. PubMed ID: 17414623
[TBL] [Abstract][Full Text] [Related]
4. Measurement of DNA cross-linking in patients on ifosfamide therapy using the single cell gel electrophoresis (comet) assay.
Hartley JM; Spanswick VJ; Gander M; Giacomini G; Whelan J; Souhami RL; Hartley JA
Clin Cancer Res; 1999 Mar; 5(3):507-12. PubMed ID: 10100700
[TBL] [Abstract][Full Text] [Related]
5. Metabolism of ifosfamide to chloroacetaldehyde contributes to antitumor activity in vivo.
Börner K; Kisro J; Brüggemann SK; Hagenah W; Peters SO; Wagner T
Drug Metab Dispos; 2000 May; 28(5):573-6. PubMed ID: 10772637
[TBL] [Abstract][Full Text] [Related]
6. SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 1: cellular pharmacology, in vitro and initial in vivo antitumor activity.
Hartley JA; Spanswick VJ; Brooks N; Clingen PH; McHugh PJ; Hochhauser D; Pedley RB; Kelland LR; Alley MC; Schultz R; Hollingshead MG; Schweikart KM; Tomaszewski JE; Sausville EA; Gregson SJ; Howard PW; Thurston DE
Cancer Res; 2004 Sep; 64(18):6693-9. PubMed ID: 15374986
[TBL] [Abstract][Full Text] [Related]
7. Structure-activity study with bioreductive benzoquinone alkylating agents: effects on DT-diaphorase-mediated DNA crosslink and strand break formation in relation to mechanisms of cytotoxicity.
Fourie J; Guziec F; Guziec L; Monterrosa C; Fiterman DJ; Begleiter A
Cancer Chemother Pharmacol; 2004 Mar; 53(3):191-203. PubMed ID: 14614574
[TBL] [Abstract][Full Text] [Related]
8. Ifosfamide cytotoxicity on human tumor and renal cells: role of chloroacetaldehyde in comparison to 4-hydroxyifosfamide.
Brüggemann SK; Kisro J; Wagner T
Cancer Res; 1997 Jul; 57(13):2676-80. PubMed ID: 9205076
[TBL] [Abstract][Full Text] [Related]
9. Low sensitivity of the comet assay to detect acetaldehyde-induced genotoxicity.
Speit G; Fröhler-Keller M; Schütz P; Neuss S
Mutat Res; 2008 Dec; 657(2):93-7. PubMed ID: 18755289
[TBL] [Abstract][Full Text] [Related]
10. Preclinical evaluation of the pharmacodynamic properties of 2,5-diaziridinyl-3-hydroxymethyl-6-methyl-1,4-benzoquinone.
Ward TH; Danson S; McGown AT; Ranson M; Coe NA; Jayson GC; Cummings J; Hargreaves RH; Butler J
Clin Cancer Res; 2005 Apr; 11(7):2695-701. PubMed ID: 15814651
[TBL] [Abstract][Full Text] [Related]
11. Formation of interstrand cross-links in chloroacetaldehyde-treated DNA demonstrated by ethidium bromide fluorescence.
Spengler SJ; Singer B
Cancer Res; 1988 Sep; 48(17):4804-6. PubMed ID: 3409221
[TBL] [Abstract][Full Text] [Related]
12. Toxicity of ifosfamide and its metabolite chloroacetaldehyde in cultured renal tubule cells.
Springate J; Chan K; Lu H; Davies S; Taub M
In Vitro Cell Dev Biol Anim; 1999 Jun; 35(6):314-7. PubMed ID: 10476917
[TBL] [Abstract][Full Text] [Related]
13. Melphalan-induced DNA damage in p53(+/-) and wild type mice analysed by the comet assay.
Cordelli E; Cinelli S; Lascialfari A; Ranaldi R; Pacchierotti F
Mutat Res; 2004 Jun; 550(1-2):133-43. PubMed ID: 15135647
[TBL] [Abstract][Full Text] [Related]
14. Validation of the comet-X assay as a pharmacodynamic assay for measuring DNA cross-linking produced by the novel anticancer agent RH1 during a phase I clinical trial.
Danson S; Ranson M; Denneny O; Cummings J; Ward TH
Cancer Chemother Pharmacol; 2007 Nov; 60(6):851-61. PubMed ID: 17333193
[TBL] [Abstract][Full Text] [Related]
15. Targets of chloroacetaldehyde-induced nephrotoxicity.
Knouzy B; Dubourg L; Baverel G; Michoudet C
Toxicol In Vitro; 2010 Feb; 24(1):99-107. PubMed ID: 19733226
[TBL] [Abstract][Full Text] [Related]
16. Unsymmetrical DNA cross-linking agents: combination of the CBI and PBD pharmacophores.
Tercel M; Stribbling SM; Sheppard H; Siim BG; Wu K; Pullen SM; Botting KJ; Wilson WR; Denny WA
J Med Chem; 2003 May; 46(11):2132-51. PubMed ID: 12747786
[TBL] [Abstract][Full Text] [Related]
17. hOGG1 recognizes oxidative damage using the comet assay with greater specificity than FPG or ENDOIII.
Smith CC; O'Donovan MR; Martin EA
Mutagenesis; 2006 May; 21(3):185-90. PubMed ID: 16597659
[TBL] [Abstract][Full Text] [Related]
18. Novel DNA-directed alkylating agents: design, synthesis and potent antitumor effect of phenyl N-mustard-9-anilinoacridine conjugates via a carbamate or carbonate linker.
Kapuriya N; Kapuriya K; Dong H; Zhang X; Chou TC; Chen YT; Lee TC; Lee WC; Tsai TH; Naliapara Y; Su TL
Bioorg Med Chem; 2009 Feb; 17(3):1264-75. PubMed ID: 19124250
[TBL] [Abstract][Full Text] [Related]
19. DNA alkylation and interstrand cross-linking by treosulfan.
Hartley JA; O'Hare CC; Baumgart J
Br J Cancer; 1999 Jan; 79(2):264-6. PubMed ID: 9888467
[TBL] [Abstract][Full Text] [Related]
20. Potent antitumor bifunctional DNA alkylating agents, synthesis and biological activities of 3a-aza-cyclopenta[a]indenes.
Kakadiya R; Dong H; Lee PC; Kapuriya N; Zhang X; Chou TC; Lee TC; Kapuriya K; Shah A; Su TL
Bioorg Med Chem; 2009 Aug; 17(15):5614-26. PubMed ID: 19576785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
